Comparison of oral fluconazole and itraconazole for progressive, nonmeningeal coccidioidomycosis

A randomized, double-blind trial

John N Galgiani, A. Catanzaro, G. A. Cloud, R. H. Johnson, P. L. Williams, L. F. Mirels, F. Nassar, J. E. Lutz, D. A. Stevens, P. K. Sharkey, V. R. Singh, R. A. Larsen, K. L. Delgado, C. Flanigan, M. G. Rinaldi

Research output: Contribution to journalArticle

188 Citations (Scopus)

Abstract

Background: In previous open-label noncomparative clinical trials, both fluconazole and itraconazole were effective therapy for progressive forms of coccidioidomycosis. Objective: To determine whether fluconazole or itraconazole is superior for treatment of nonmeningeal progressive coccidioidal infections. Design: Randomized, double-blind, placebo-controlled trial. Setting: 7 treatment centers in California, Arizona, and Texas. Patients: 198 patients with chronic pulmonary, soft tissue, or skeletal coccidioidal infections. Intervention: Oral fluconazole, 400 mg/d, or itraconazole, 200 mg twice daily. Measurements: After 4, 8, and 12 months, a predefined scoring system was used to assess severity of infection. Findings were compared with those at baseline. Results: Overall, 50% of patients (47 of 94) and 63% of patients (61 of 97) responded to 8 months of treatment with fluconazole and itraconazole, respectively (difference, 13 percentage points [95% CI, -2 to 28 percentage points]; P = 0.08). Patients with skeletal infections responded twice as frequently to itraconazole as to fluconazole. By 12 months, 57% of patients had responded to fluconazole and 72% had responded to itraconazole (difference, 15 percentage points [CI, 0.003 to 30 percentage points]; P = 0.05). Soft tissue disease was associated with increased likelihood of response, as in previous studies. Azole drug was detected in serum specimens from all but 3 patients; however, drug concentrations were not helpful in predicting outcome. Relapse rates after discontinuation of therapy did not differ significantly between groups (28% after fluconazole treatment and 18% after itraconazole treatment). Both drugs were well tolerated. Conclusions: Neither fluconazole nor itraconazole showed statistically superior efficacy in nonmeningeal coccidioidomycosis, although there is a trend toward slightly greater efficacy with itraconazole at the doses studied.

Original languageEnglish (US)
Pages (from-to)676-686
Number of pages11
JournalAnnals of Internal Medicine
Volume133
Issue number9
StatePublished - Nov 7 2000

Fingerprint

Coccidioidomycosis
Itraconazole
Fluconazole
Infection
Therapeutics
Pharmaceutical Preparations
Azoles
Placebos
Clinical Trials
Recurrence
Lung

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Galgiani, J. N., Catanzaro, A., Cloud, G. A., Johnson, R. H., Williams, P. L., Mirels, L. F., ... Rinaldi, M. G. (2000). Comparison of oral fluconazole and itraconazole for progressive, nonmeningeal coccidioidomycosis: A randomized, double-blind trial. Annals of Internal Medicine, 133(9), 676-686.

Comparison of oral fluconazole and itraconazole for progressive, nonmeningeal coccidioidomycosis : A randomized, double-blind trial. / Galgiani, John N; Catanzaro, A.; Cloud, G. A.; Johnson, R. H.; Williams, P. L.; Mirels, L. F.; Nassar, F.; Lutz, J. E.; Stevens, D. A.; Sharkey, P. K.; Singh, V. R.; Larsen, R. A.; Delgado, K. L.; Flanigan, C.; Rinaldi, M. G.

In: Annals of Internal Medicine, Vol. 133, No. 9, 07.11.2000, p. 676-686.

Research output: Contribution to journalArticle

Galgiani, JN, Catanzaro, A, Cloud, GA, Johnson, RH, Williams, PL, Mirels, LF, Nassar, F, Lutz, JE, Stevens, DA, Sharkey, PK, Singh, VR, Larsen, RA, Delgado, KL, Flanigan, C & Rinaldi, MG 2000, 'Comparison of oral fluconazole and itraconazole for progressive, nonmeningeal coccidioidomycosis: A randomized, double-blind trial', Annals of Internal Medicine, vol. 133, no. 9, pp. 676-686.
Galgiani, John N ; Catanzaro, A. ; Cloud, G. A. ; Johnson, R. H. ; Williams, P. L. ; Mirels, L. F. ; Nassar, F. ; Lutz, J. E. ; Stevens, D. A. ; Sharkey, P. K. ; Singh, V. R. ; Larsen, R. A. ; Delgado, K. L. ; Flanigan, C. ; Rinaldi, M. G. / Comparison of oral fluconazole and itraconazole for progressive, nonmeningeal coccidioidomycosis : A randomized, double-blind trial. In: Annals of Internal Medicine. 2000 ; Vol. 133, No. 9. pp. 676-686.
@article{6056fb19f489497bb8c6dbef98135814,
title = "Comparison of oral fluconazole and itraconazole for progressive, nonmeningeal coccidioidomycosis: A randomized, double-blind trial",
abstract = "Background: In previous open-label noncomparative clinical trials, both fluconazole and itraconazole were effective therapy for progressive forms of coccidioidomycosis. Objective: To determine whether fluconazole or itraconazole is superior for treatment of nonmeningeal progressive coccidioidal infections. Design: Randomized, double-blind, placebo-controlled trial. Setting: 7 treatment centers in California, Arizona, and Texas. Patients: 198 patients with chronic pulmonary, soft tissue, or skeletal coccidioidal infections. Intervention: Oral fluconazole, 400 mg/d, or itraconazole, 200 mg twice daily. Measurements: After 4, 8, and 12 months, a predefined scoring system was used to assess severity of infection. Findings were compared with those at baseline. Results: Overall, 50{\%} of patients (47 of 94) and 63{\%} of patients (61 of 97) responded to 8 months of treatment with fluconazole and itraconazole, respectively (difference, 13 percentage points [95{\%} CI, -2 to 28 percentage points]; P = 0.08). Patients with skeletal infections responded twice as frequently to itraconazole as to fluconazole. By 12 months, 57{\%} of patients had responded to fluconazole and 72{\%} had responded to itraconazole (difference, 15 percentage points [CI, 0.003 to 30 percentage points]; P = 0.05). Soft tissue disease was associated with increased likelihood of response, as in previous studies. Azole drug was detected in serum specimens from all but 3 patients; however, drug concentrations were not helpful in predicting outcome. Relapse rates after discontinuation of therapy did not differ significantly between groups (28{\%} after fluconazole treatment and 18{\%} after itraconazole treatment). Both drugs were well tolerated. Conclusions: Neither fluconazole nor itraconazole showed statistically superior efficacy in nonmeningeal coccidioidomycosis, although there is a trend toward slightly greater efficacy with itraconazole at the doses studied.",
author = "Galgiani, {John N} and A. Catanzaro and Cloud, {G. A.} and Johnson, {R. H.} and Williams, {P. L.} and Mirels, {L. F.} and F. Nassar and Lutz, {J. E.} and Stevens, {D. A.} and Sharkey, {P. K.} and Singh, {V. R.} and Larsen, {R. A.} and Delgado, {K. L.} and C. Flanigan and Rinaldi, {M. G.}",
year = "2000",
month = "11",
day = "7",
language = "English (US)",
volume = "133",
pages = "676--686",
journal = "Annals of Internal Medicine",
issn = "0003-4819",
publisher = "American College of Physicians",
number = "9",

}

TY - JOUR

T1 - Comparison of oral fluconazole and itraconazole for progressive, nonmeningeal coccidioidomycosis

T2 - A randomized, double-blind trial

AU - Galgiani, John N

AU - Catanzaro, A.

AU - Cloud, G. A.

AU - Johnson, R. H.

AU - Williams, P. L.

AU - Mirels, L. F.

AU - Nassar, F.

AU - Lutz, J. E.

AU - Stevens, D. A.

AU - Sharkey, P. K.

AU - Singh, V. R.

AU - Larsen, R. A.

AU - Delgado, K. L.

AU - Flanigan, C.

AU - Rinaldi, M. G.

PY - 2000/11/7

Y1 - 2000/11/7

N2 - Background: In previous open-label noncomparative clinical trials, both fluconazole and itraconazole were effective therapy for progressive forms of coccidioidomycosis. Objective: To determine whether fluconazole or itraconazole is superior for treatment of nonmeningeal progressive coccidioidal infections. Design: Randomized, double-blind, placebo-controlled trial. Setting: 7 treatment centers in California, Arizona, and Texas. Patients: 198 patients with chronic pulmonary, soft tissue, or skeletal coccidioidal infections. Intervention: Oral fluconazole, 400 mg/d, or itraconazole, 200 mg twice daily. Measurements: After 4, 8, and 12 months, a predefined scoring system was used to assess severity of infection. Findings were compared with those at baseline. Results: Overall, 50% of patients (47 of 94) and 63% of patients (61 of 97) responded to 8 months of treatment with fluconazole and itraconazole, respectively (difference, 13 percentage points [95% CI, -2 to 28 percentage points]; P = 0.08). Patients with skeletal infections responded twice as frequently to itraconazole as to fluconazole. By 12 months, 57% of patients had responded to fluconazole and 72% had responded to itraconazole (difference, 15 percentage points [CI, 0.003 to 30 percentage points]; P = 0.05). Soft tissue disease was associated with increased likelihood of response, as in previous studies. Azole drug was detected in serum specimens from all but 3 patients; however, drug concentrations were not helpful in predicting outcome. Relapse rates after discontinuation of therapy did not differ significantly between groups (28% after fluconazole treatment and 18% after itraconazole treatment). Both drugs were well tolerated. Conclusions: Neither fluconazole nor itraconazole showed statistically superior efficacy in nonmeningeal coccidioidomycosis, although there is a trend toward slightly greater efficacy with itraconazole at the doses studied.

AB - Background: In previous open-label noncomparative clinical trials, both fluconazole and itraconazole were effective therapy for progressive forms of coccidioidomycosis. Objective: To determine whether fluconazole or itraconazole is superior for treatment of nonmeningeal progressive coccidioidal infections. Design: Randomized, double-blind, placebo-controlled trial. Setting: 7 treatment centers in California, Arizona, and Texas. Patients: 198 patients with chronic pulmonary, soft tissue, or skeletal coccidioidal infections. Intervention: Oral fluconazole, 400 mg/d, or itraconazole, 200 mg twice daily. Measurements: After 4, 8, and 12 months, a predefined scoring system was used to assess severity of infection. Findings were compared with those at baseline. Results: Overall, 50% of patients (47 of 94) and 63% of patients (61 of 97) responded to 8 months of treatment with fluconazole and itraconazole, respectively (difference, 13 percentage points [95% CI, -2 to 28 percentage points]; P = 0.08). Patients with skeletal infections responded twice as frequently to itraconazole as to fluconazole. By 12 months, 57% of patients had responded to fluconazole and 72% had responded to itraconazole (difference, 15 percentage points [CI, 0.003 to 30 percentage points]; P = 0.05). Soft tissue disease was associated with increased likelihood of response, as in previous studies. Azole drug was detected in serum specimens from all but 3 patients; however, drug concentrations were not helpful in predicting outcome. Relapse rates after discontinuation of therapy did not differ significantly between groups (28% after fluconazole treatment and 18% after itraconazole treatment). Both drugs were well tolerated. Conclusions: Neither fluconazole nor itraconazole showed statistically superior efficacy in nonmeningeal coccidioidomycosis, although there is a trend toward slightly greater efficacy with itraconazole at the doses studied.

UR - http://www.scopus.com/inward/record.url?scp=0034619472&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034619472&partnerID=8YFLogxK

M3 - Article

VL - 133

SP - 676

EP - 686

JO - Annals of Internal Medicine

JF - Annals of Internal Medicine

SN - 0003-4819

IS - 9

ER -